ArticleMalaria journal2026
Efficacy of artemether-lumefantrine combination for the treatment of uncomplicated Plasmodium falciparum malaria after 16 years of its introduction into Ghana's antimalarial medicines policy.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundArtemether-lumefantrine (AL) was introduced into Ghana's antimalarial medicines policy in 2008 as an alternative to artesunate-amodiaquine (AS-AQ) for the treatment of uncomplicated malaria. Studies conducted between 2010 and 2021 had shown the efficacy of AL to be above 90%. This study aimed at determining the current efficacy of AL in 10 sentinel sites after 16 years of its formal introduction as one of the first-line medicines for uncomplicated malaria in the country.
methodsThe study was conducted among febrile children aged 6 months to 9 years between August 2024 and January 2025 using the WHO protocol for surveillance of antimalarial drug efficacy and reported using the standardized antimalarial therapeutic efficacy reporting (STARTER) checklist. Children enrolled were followed-up for 28 days. Parasite recrudescence and re-infections were determined using merozoite surface protein 1 (msp1), merozoite surface protein 2 (msp2), and one microsatellite (poly-α) in the recommended 3/3 PCR-genotyping approach.
resultsOut of 1387 suspected uncomplicated malaria cases screened, 747 met the inclusion criteria and were subsequently enrolled. Out of this, 738 completed their follow-up visits. PCR-uncorrected cure rates across the 10 sentinel sites ranged between 85.9% (95% CI 76.6-92.5) and 100% with a national rate of 96.3% (95% CI 94.7-97.6) whilst PCR-corrected cure rates ranged between 91.9% (95% CI 78.1-98.3) and 100% with a national rate of 98.9% (95% CI 97.8-99.5). No early treatment failures were observed at any of the sites. Also, no child enrolled was parasitaemic on Day 3.
conclusionsAL has remained highly efficacious (> 90%) in the treatment of uncomplicated malaria in Ghana, even after 16 years of its formal introduction into the country's antimalarial medicines policy. Preserving this high efficacy through strategies such as the deliberate implementation of multiple first-line therapy (MFT) has become critical, particularly as lumefantrine is needed for the development of non-artemisinin combination therapies in response to the spread of artemisinin resistance. Trial Registration Pan African Clinical Trial Registry-PACTR202502791855505.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.